NCT/Study#

NCT02332850 /

139511-MMRC

A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: